| INTRODUCTION
Treatment of advanced PCa faces a challenge because patients with high risk recurrent PCa develops the resistance to androgen deprivation therapy (ADT) and their tumors become castration resistant PCa (CRPC). 1 There are two tangled, overlapped signaling pathways, including androgen receptor dependent signaling pathway (ARSP) and non-ARSP (NARSP) in CRPC. Preclinical and clinical studies have confirmed that drugs targeting to NARSPs, such as Notch, 2, 3 Wnt, 4, 5 DNA repair signaling, 6 showed a single or synergistic efficacy in the treatment of CRPC. The PI3K/Akt/mTOR signaling, a NARSP, is crucial for the development and maintenance of CRPC. [7] [8] [9] However, some inhibitors targeting to this signaling, such as the mTOR inhibitor Everolimus, showed an unsatisfied effect in the treatment of Zhixiong Chen and Qilong Jiang contributed equally to this work.
CRPC. 10, 11 Currently, the precise mechanisms underlying the resistance to Everolimus in CRPC are unclear, and there is no reliable biomarker to predict the sensitivity to Everolimus in CRPC patients.
Nitrogen permease regulator-like 2 (NPRL2) is known as tumorsuppressor candidate 4 (TUSC4). 12 Previous studies have shown that NPRL2 in the GATOR1 complex inhibits the mTOR signaling. [13] [14] [15] It is well known that the mTORC1 negatively regulates autophagy, a conserved process to maintain homeostasis by recycling macromolecules and organelles to form double-membrane autophagosome vesicles. 16, 17 Autophagy can function as an adaptive response to maintain cell survival and growth. Notably, several studies [18] [19] [20] have established that autophagy is associated with drug resistance to ADT and inhibitors of the PI3K/Akt/mTOR signaling. Actually, inhibition of NPRL2 impedes autophagic flux in breast cancer cells. 21 Interestingly, high levels of NPRL2 expression are associated with resistance to the mTOR inhibitor Rapamycin in several types of cancer cells, 22 suggesting a potential relationship between NPRL2 and efficacy of Everolimus. However, there is no report on the expression and potential role of NPRL2 in CRPC.
In this study, we tested the hypothesis that high levels of NPRL2 expression could inhibit the mTOR signaling and enhance autophagy and resistance to Everolimus in CRPC. To address it, we characterized the NPRL2 expression in PCa and CRPC. Subsequently, we employed the loss or gain function of NPRL2 to determine the role of NPRL2 in regulating the proliferation, sensitivity to Everolimus, the mTOR signaling, autophagy in CRPC. Our data indicated that high levels of NPRL2 expression in CRPC promoted the resistance to Everolimus by enhancing autophagy. 
| Primary reagents
Rabbit anti-NPRL2, p62/SQSTM1, Bcl-2, Vinculin, and α-tubulin were purchased from Proteintech (Proteintech Group, Inc., Rosemont, IL);
Rabbit anti-p-mTOR, p-S6 K, rabbit anti-PARP, mouse anti-mTOR and mouse anti-S6K were purchase from Cell Signaling (Cell Signaling TRizol, Prime Script RT reagent kit, and SYBR Premix Ex TaqTM II kit were purchased from Takara (Takara Biotechnology Inc., Tokyo, Japan).
| Immunohistochemistry
The paraffin-embedded tissue section (4 μm) were deparaffinized, 
| Immumofluorescence
Individual groups of cells were cultured on glass cover slips and fixed with 
| Quantitative real-time PCR (RT-PCR)
Total RNA was extracted from individual groups of cells using TRizol.
After qualification and quantification by spectrophotometer, the RNA samples were reversely transcribed into cDNA using the Prime Script RT reagent kit, according to the manufacturer's protocols. The relative levels of NPRL2mRNA transcripts were determined by quantitative RT-PCR using the SYBR Premix Ex TaqTM II kit and specific primers.
The sequences of primers were sense 5′CAGAAGTATCCTGTGCGG
GTGA-3′ and antisense 5′-CATTTTCAAGCCGCTCATCC-3′ for NPRL2;sense 5′-CTTTGGTATCGTGGAAGGACTC-3′ and antisense 5′-GTAGAGGCAGGGATGATGTTCT-3′ for GAPDH. The data were analyzed by 2 −△△Ct method.
| Western blot
Individual groups of cells were lyzed in RIPA buffer containing protease inhibitor PMSF and phosphatase inhibitors. Similarly, the xenograft tumor tissues were collected and homogenized in RIPA. After centrifugation, the cell and tumor tissue lysates were separated by sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-PAGE) on 8-12% gels and transferred on polyvinylidenedifluoride (PVDF) membrane. The membranes were blocked with 5% Phospho Blocker or 5% skim milk in TBST and incubated with primary antibodies. The bound antibodies were detected with HRP-conjugated second antibodies (Zhongshan Golden Bridge Bio-technology, China) and visualized using the chemiluminescent detection system (Millipore, Germany). The relative levels of target protein to the control were determined. was monitored every 5-day and the tumor volumes were calculated by the formula described previously. 26 At the end of the experiment, the mice were sacrificed and their tumors were dissected and imaged. The tumor tissues were subjected to Western blot analysis.
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| Statistical analysis
The cells were tested in triplicate and the experiments were repeated at for three times. Data are expressed as means ± S.D. 
| NPRL2 enhances autophagy, survival, and resistance to Everolimus in CRPC cells
The mTOR signaling is a negative regulator of autophagy, which is usually associated with drug resistance and cell survival under harsh conditions of metabolic stress in tumor microenvironment induced by chemotherapy, nutritional starvation, oxidative stress in cancer cells. 17 Given that NPRL2 downregulated the mTOR signaling, we tested whether an altered NPRL2 expression could alter autophagy and cell survival when combined with Everolimus in PCa cells. In comparison with the control, NPRL2 silencing reduced the percentages of autophagic cells while NPRL2 over-expression increased the percentages of autophagic cells ( Figures 4A and 4B) . Similarly, NPRL2 silencing decreased the relative levels of LC3-II to LC3-I, but increased the levels of p62 expression in PC3 and LNPER cells ( Figure 4C ). In contrast, NPRL2 over-expression increased the relative levels of LC3-II to LC3-I, but decreased the levels of p62 expression in PC3 and LNPER cells ( Figure 4C ). Next, we investigated the effects of Everolimus and/or 
| DISCUSSION
NPRL2 has been thought to be a tumor suppressor candidate gene in cancers and its expression is down-regulated in several types of cancers.
Furthermore, NPRL2 can inhibit cancer cell proliferation by inducing cell cycle arrest and apoptosis. 27, 28 Interestingly, we found that NPRL2
promoted the growth of CRPC. Evidentially, higher levels of NPRL2 expression were detected in PCa, particularly in CRPC tissues and cells. To understand the molecular mechanisms underlying the action of NPRL2, we tested the effect of altered NPRL2 expression on the mTOR activation, autophagy, and sensitivity to Everolimus in CRPC cells. We found that NPRL2 over-expression attenuated the mTOR activation and enhanced autophagy while NPRL2 silencing enhanced the mTOR signaling, but decreased autophagy in CRPC cells. These data were consistent with previous findings in other types of cells, 13, 15, 21 supporting the notion that NPRL2 is a regulator of autophagy. The enhanced autophagy by NPRL2 may support the survival and growth of PCa in a hash tumor environment. 13, 16 Notably,
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Continued. Figure 4E and Figure 5C ). Our data support the notion that inhibition of autophagy sensitizes CRPC cells to ATD therapy, 20, 35, 36 Docetaxel, 37 Salinomycin. 38 Actually, combination of the PI3K/Akt inhibitor and autophagy inhibitors increases their therapeutic effect on PCa. 19, 39 These findings indicate that CRPC tumors with high NPRL2
expression are prone to development of resistance to Everolimus and combination of Everolimus and an inhibitor of NPRL2 may be valuable for intervention of CRPC tumors. Therefore, our findings may aid in design of new therapies for treatment of CRPC.
| CONCLUSIONS
Together, NPRL2 may act as a pro-growth factor in PCa, and the high levels of NPRL2 expression in CRPC promote resistance to Everolimus by enhancing autophagy. NPRL2 may be a new therapeutic target for intervention of CRPC and a biomarker for predicting resistance to Everolimus in CRPC.
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